Chagas Disease Clinical Trial
Official title:
Observational Pregnancy Safety Study of Women Exposed to Nifurtimox During Pregnancy to Describe the Risk of Pregnancy and Maternal Complications and Other Events of Interest on the Developing Fetus, Neonate, and Infant
This is an observational study in which data from women with Chagas disease who will take or have already taken nifurtimox during pregnancy and the impact on their babies are studied. Chagas disease is an inflammatory, infectious disease caused by the parasite Trypanosoma cruzi. This parasite is mainly spread by insects called triatomine bug. If Chagas disease is left untreated, it can later cause e.g. serious heart and digestive problems. Nifurtimox has been used for more than 50 years to treat Chagas disease in children and adults. It is not recommended to be used during pregnancy as data from animal studies indicate that it may harm the baby. Currently, there are not enough data to know if this is also the case in humans. In this study, researchers want to collect data on the safety of nifurtimox use in pregnant women. To do this, researchers will collect the following information: - Birth defects (abnormal and problematic structures or functions, a child is born with) - Pregnancy outcomes (like live birth, preterm birth, still birth/death of the unborn baby, miscarriage, or abortion) - Certain health problems of the child up to 12 months of age - Certain health problems of the women experienced during pregnancy The data will be collected from different sources including telephone calls with the women or their doctor, CRFs (case reprt forms) or from medical records The researchers will compare the proportion of children with birth defects, pregnancy outcomes or certain health problems of the child or the women during pregnancy with available data on these outcomes in the general population. The study will run for approximately 10 years.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01162967 -
Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole
|
Phase 2 | |
Completed |
NCT00023556 -
Genetic Architecture of Heart Disease in Rural Brazil
|
N/A | |
Active, not recruiting |
NCT04024163 -
Prospective Study of Benznidazole for Chagas' Disease Children With Chronic Indeterminate Chagas Disease
|
Phase 3 | |
Recruiting |
NCT05868005 -
Delivering a Multi-disease Screening Tool to Migrant Populations
|
N/A | |
Completed |
NCT03892213 -
Pharmacokinetic Drug-Drug Interaction Study
|
Phase 1 | |
Recruiting |
NCT00875173 -
Selenium Treatment and Chagasic Cardiopathy (STCC)
|
Phase 3 | |
Recruiting |
NCT03704181 -
Colchicine for Patients With Chagas´ Disease( B1 Stage)
|
Phase 2 | |
Active, not recruiting |
NCT03378661 -
BENDITA BEnznidazole New Doses Improved Treatment and Associations
|
Phase 2 | |
Completed |
NCT01927224 -
Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients
|
Phase 1 | |
Completed |
NCT01006486 -
Outcomes of an Anticoagulation Clinic in an University Hospital
|
Phase 4 | |
Completed |
NCT00123916 -
BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease
|
Phase 3 | |
Completed |
NCT02516293 -
Cardiac Rehabilitation in Chagas Heart Failure
|
Phase 2/Phase 3 | |
Completed |
NCT02517632 -
Physical Exercise Program in Chronic Chagas Heart Disease
|
Phase 3 | |
Recruiting |
NCT02099903 -
Renal Denervation in Patients With Heart Failure Secondary to Chagas Disease
|
N/A | |
Completed |
NCT01874795 -
Effect of Ganglionar Electrical Stimulation on Central Arterial Pressure
|
N/A | |
Completed |
NCT01006473 -
Exercise Training in Chagas Cardiomyopathy
|
Phase 4 | |
Completed |
NCT02386358 -
Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Clinical Trial
|
Phase 3 | |
Completed |
NCT02346123 -
Determination of Genetic Polymorphisms in Chronic Chagas Cardiomyopathy
|
N/A | |
Recruiting |
NCT02295215 -
Exercise Training in Patients With Chagasic Heart Disease Without Ventricular Dysfunction
|
N/A | |
Completed |
NCT03350295 -
Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg
|
Phase 1 |